AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04011787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolic Profile
Description: Bloods will be taken to assess all patients metabolic profile
Study NCT04011787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic Profile
Description: Bloods will be taken to assess all patients metabolic profile
Study NCT04011787 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Chest X-ray
Description: A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
Study NCT04011787 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
Study NCT06445478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restrictive Exercise and Isokinetic Exercise
Description: Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants.
Study NCT06334497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letermovir placebo
Description: 480mg (2X240mg- tablets) of Letermovir placebo given orally once a day until the treatment success or the treatment failure, up to 12 weeks
Study NCT05630469 — intervention group
Intervention type: OTHER
Intervention: Electroconvulsive therapy
Description: repetitive induction of a generalized seizure under controlled conditions (muscle relaxation and sedation)
Study NCT05922423 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
Study NCT05238896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet [Olumiant]
Description: Baricitinib 4 mg/d oral route for 42 days
Study NCT05238896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
Study NCT04742153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT06446323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 ml dose of sucrose
Description: Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
Study NCT06506513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: High-intensity interval training
Study NCT06506513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise training
Description: Moderate intensity exercise training
Study NCT06506513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity exercise training
Description: Low intensity exercise training
Study NCT05336760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Iowa Oral Performance Instrument (IOPI)
Description: IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
Study NCT05336760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mann Assessment of Swallowing Ability (MASA)
Description: MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
Study NCT05336760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
Study NCT05336760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory function measurements
Description: Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
Study NCT05553548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biologically oriented alveolar ridge preservation
Description: xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
Study NCT05553548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenogenic bone graft in entire (apico-coronal) extension
Description: xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
Study NCT04955145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RUTA C 60
Description: Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
Study NCT06103799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB model-based continuity of care
Description: The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
Study NCT03817593 — intervention group
Intervention type: OTHER
Intervention: Transcendental Meditation (TM)
Description: Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
Study NCT05639543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INT-787
Description: Blinded Study Drug
Study NCT05639543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04904653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm
Study NCT04904653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No sealant (liquid, gel or patch) + suction drain
Study NCT05654519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG/LFCN and QL Blocks
Description: Bupivacaine 0.25% injection
Study NCT05139862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
Study NCT06297096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg s.c./week
Study NCT06297096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
Study NCT06297096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Study NCT06297096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Study NCT04545593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Minds Strong Bodies Enhanced
Description: The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
Study NCT04545593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
Study NCT04314973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Pelvis Orthosis
Description: Walking with the robotic device providing the assistive protocol.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fixed sleep goal
Description: Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
Study NCT04353661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin will be administered orally.
Study NCT04353661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HP xenon (¹²⁹XE)
Description: HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
Study NCT04353661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HP xenon (¹²⁹XE)
Description: HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized sleep goal
Description: Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized sleep goal
Description: Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging without virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
Study NCT04314973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercises
Description: Walking exercises without wearing the robotic device.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging with virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
Study NCT04841499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
Description: take 2 capsules orally each day for 7 days
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital sleep health messaging with virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive Parent-Directed Loss-Framed Incentive
Description: No parental incentive
Study NCT05181085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NST 6179
Description: orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
Study NCT05181085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive analogue
Study NCT06548971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
Study NCT06548971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Parent-Directed Loss-Framed Incentive
Description: Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Parent-Directed Loss-Framed Incentive
Description: Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive Supportive Feedback
Description: No supportive feedback
Study NCT06488573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: 7 individual sessions + 8 small group sessions
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211216
Description: Flavor variant P1211216 of a 1.5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213416
Description: Flavor variant P1213416 of a 1.5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213716
Description: Flavor variant P1213716 of a 1.5% nicotine ENDS product
Study NCT06548971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best medical management
Description: Patients in both groups will receive the best medical management according to the guidelines.
Study NCT06548971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical management
Description: Patients in both groups will receive the best medical management according to the guidelines.
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213616
Description: Flavor variant P1213616 of a 1.5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213816
Description: Flavor variant P1213816 of a 1.5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211916
Description: Flavor variant P1211916 of a 1.5% nicotine ENDS product
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Supportive Feedback
Description: Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1210016
Description: Flavor variant P1210016 of a 1.5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211217
Description: Flavor variant P1211217 of a 2.4% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213417
Description: Flavor variant P1213417 of a 2.4% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211222
Description: Flavor variant P1211222 of a 5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213422
Description: Flavor variant P1213422 of a 5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213722
Description: Flavor variant P1213722 of a 5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213622
Description: Flavor variant P1213622 of a 5% nicotine ENDS product
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213822
Description: Flavor variant P1213822 of a 5% nicotine ENDS product
Study NCT05703347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Supportive Feedback
Description: Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
Study NCT00540605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: topical gel containing 1% tenofovir
Study NCT05481034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMA bolus option
Description: SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
Study NCT05481034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exactly estimated carbohydrate content bolus option
Description: The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
Study NCT05118139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211922
Description: Flavor variant P1211922 of a 5% nicotine ENDS product